Background/Aims: Despite limited evidence for efficacy, granulocyte transfusions (GTX) are used to prevent and treat opportunistic infections in patients with neutropenia. Methods: Three hundred and seventy-three GTX given to 74 patients were assessed retrospectively. Results: GTX were discontinued because of clinical improvement more often in patients with severe infections than in patients without severe infections (27 vs. 12%; p ≤ 0.002), whereas deaths resulted in discontinuation of GTX therapy less often in patients with severe infections than without (8 vs. 39%; p ≤ 0.002). Patients who died by 12 weeks after GTX initiation were more likely to have leukemia (p = 0.03), not to have recovery of neutrophil counts (p < 0.0001), and to have started GTX during a critical care unit stay (p < 0.001). Uses of granulocyte colony-stimulating factor (p ≤ 0.02) and interferon-γ (p ≤ 0.04) were more common in patients who survived. In patients with comorbidities (31%; odds ratio, OR, 12.6; 95% confidence interval, CI, 2.4-65.7; p ≤ 0.003), GTX was started in the critical care unit (OR 8.8; 95% CI 2.5-30.9; p < 0.001), and a high total bilirubin level at the end of GTX (OR 2.1; 95% CI 1.1-4.2; p = 0.03) had a higher probability of death 12 weeks after GTX therapy commenced. Conclusions: The possibility that a niche population may benefit from GTX requires further assessment.

Keywords:
Granulocyte transfusions, Immunosuppression, Infection-attributed deaths, Leukemia, Life-threatening infections, Toxicity
1.
Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
2.
Bodey GP, Nies BA, Freireich EJ: Multiple organism septicemia in acute leukemia: analysis of 54 episodes. Arch Intern Med 1965;116:266-272.
3.
Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA: Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010;28:4500-4506.
4.
Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J: Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007;110:3532-3539.
5.
Safdar A, Rolston KV: Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007;45:1602-1609.
6.
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360.
7.
Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF, Champlin RE, Khouri I: Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010;45:339-347.
8.
Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH, Eastern Cooperative Oncology Group: A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485.
9.
Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wörmann B, Büchner T, Hiddemann W: Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Ann Hematol 1998;77:115-122.
10.
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-3415.
11.
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561.
12.
Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE: Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 2007;86:324-333.
13.
Safdar A, Hanna H, Boktour M, Kontoyiannis D, Hachem R, Lichtiger B, Freireich EJ, Raad I: Impact of high-dose granulocyte transfusions in patients with cancer with candidemia. Cancer 2004;101:2859-2865.
14.
Strumia MM: The effect of leukocytic cream injections in the treatment of neutropenias. Am J Med 1934;187:527-544.
15.
Graw RG Jr, Herzig G, Perry S, Henderson ES: Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med 1972;287:367-371.
16.
Higby DJ, Yates JW, Henderson ES, Holland JF: Filtration leukapharesis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med 1975;292:761-766.
17.
Vogler WR, Winston EF: A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977;63:548-555.
18.
Alavi JB, Root RK, Djerassi I, Evans AE, Gluckman SJ, MacGregor RR, Guerry D, Schreiber AD, Shaw JM, Koch P, Cooper RA: A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977;296:706-711.
19.
Herzig RH, Herzig GP, Graw RG Jr, Bull MI, Ray KK: Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 1977;296:701-705.
20.
Winston DJ, Ho WG, Gale RP: Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 1982;97:509-515.
21.
Engelfriet CO, Reesink HW: Granulocyte transfusions. Vox Sang 2000;79:59-96.
22.
Vamvakas EC, Pineda AA: Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher 1996;11:1-9.
23.
Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley SD, Chauncey TR, Bensinger WI, Boeckh M: Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002;42:1414-1421.
24.
Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, Silling G, Grimminger W, Einsele H: Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008;42:679-684.
25.
Sachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, Reil A, Bux J, Bein G, Santoso S, Weissmann N: Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood 2011;117:669-677.
26.
Bowden RA: Transfusion-transmitted cytomegalovirus infection. Hematol Oncol Clin North Am 1995;9:155-166.
27.
Chemaly RF, Torres HA, Hachem R, Kontoyiannis DP, Safdar A, Raad II: Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. Haematologica 2008;93:157-158.
28.
Lowenthal RM, Grossman L, Goldman JM, Storring RA, Buskard NA, Park DS, Murphy BC, Spiers AS, Galton DA: Granulocyte transfusions in treatment of infections in patients with acute leukaemia and aplastic anaemia. Lancet 1975;i:353-358.
29.
Grigull L, Pulver N, Goudeva L, Sykora KW, Linderkamp C, Beilken A, Seidemann K, Schmid H, Welte K, Heuft HG: G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis. Support Care Cancer 2006;14:910-916.
30.
Seidel MG, Minkov M, Witt V, Matthes-Martin S, Pötschger U, Worel N, Leitner G, Stary J, Gadner H, Peters C: Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol 2009;31:166-172.
31.
Sachs UJ, Reiter A, Walter T, Bein G, Woessmann W: Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion 2006;46:1909-1914.
32.
Rutella S, Pierelli L, Sica S, Serafini R, Chiusolo P, Paladini U, Leone F, Zini G, D'Onofrio G, Leone G, Piccirillo N: Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy 2003;5:19-30.
33.
Petersen FB, Buckner CD, Clift RA, Nelson N, Counts GW, Meyers JD, Thomas ED: Prevention of nosocomial infections in marrow transplant patients: a prospective randomized comparison of systemic antibiotics versus granulocyte transfusions. Infect Control 1986;7:586-592.
34.
Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Böhme A, Hoelzer D, Martin H: Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005;84:734-741.
35.
Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley SD, Chauncey TR, Bensinger WI, Boeckh M: Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002;42:1414-1421.
36.
Morse EE, Synder E, Blumberg N, Katz AJ: Analysis of two types of granulocyte transfusions in patients with acute leukemia and septicemia. Ann Clin Lab Sci 1982;12:106-110.
37.
Briones MA, Josephson CD, Hillyer CD: Granulocyte transfusion: revisited. Curr Hematol Rep 2003;2:522-527.
38.
Cesaro S, Chinello P, De Silvestro G, Marson P, Picco G, Varotto S, Pittalis S, Zanesco L: Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer 2003;11:101-106.
39.
Sica S, Rutella S, Di Mario A, Salutari P, Rumi C, Ortu la Barbera E, Etuk B, Menichella G, D'Onofrio G, Leone G: rhG-CSF in healthy donors: mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leukocytes. J Hematother 1996;5:391-397.
40.
Drewniak A, Tool AT, Geissler J, van Bruggen R, van den Berg TK, Kuijpers TW: Toll-like receptor-induced reactivity and strongly potentiated IL-8 production in granulocytes mobilized for transfusion purposes. Blood 2010;115:4588-4596.
41.
Safdar A: Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006;38:327-337.
42.
Safdar A, Rodriguez G, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE: Recombinant interferon gamma1b immune enhancement in 20 patients with hematological malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006;106:2664-2671.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.